MitoRx Therapeutics
Business Services · United Kingdom · 1-10 Employees
View Company Info for Free
Overview
Headquarters
900 Garsington Road, Oxford, Oxfordshire...Phone Number
+44 1235838631Website
www.mitorxtherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About MitoRx Therapeutics
MitoRx Therapeutics specializes in developing first-in-class small molecule therapeutics that modulate mitochondrial metabolism, primarily targeting obesity and other cardiometabolic diseases. Their innovative approach aims to facilitate weight loss while preserving lean mass, utilizing mitochondrial-targeted compounds that have shown efficacy in various metabolic disease models. The company is based in Oxford and Cambridge, UK, and is advancing two core programs towards clinical application. MitoRx Therapeutics seeks partnerships for research collaborations in obesity-related indications and other cardiometabolic conditions.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is MitoRx Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
MitoRx Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if MitoRx Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if MitoRx Therapeutics had a recent Job posting/layoffs
Check out if MitoRx Therapeutics is spiking on competitors!
Product Launch: Get notified when MitoRx Therapeutics launches new products
Funding: Get notified immidiatlly once MitoRx Therapeutics has new funding data
Earning: See what the market has to say on MitoRx Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at MitoRx Therapeutics
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to MitoRx Therapeutics
Compare insights from companies similar to MitoRx Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
MitoRx Therapeutics
<$5M
1-10
Private
$5M
2021
N/A
Company Profile Activity
Activity Insights
MitoRx Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
MitoRx Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about MitoRx Therapeutics.
MitoRx Therapeutics financials insights
Gather financial insights about MitoRx Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Angel/Seed
$5M
MitoRx Therapeutics Tech Stack
A closer look at the technologies used by MitoRx Therapeutics
See more technologies
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Executive Move
Executive Moves, Board of Directors
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
MitoRx Therapeutics News & Media
MitoRx Therapeutics to present new data on MTRX31, its novel mitochondrial-targeted small molecule, at the 62nd EASD Annual Meeting 2026
Harwell, Oxford, UK – 17 September 2026: MitoRx Therapeutics (“MitoRx”), a biotech company targeting the restoration of healthy mitochondrial metabolism in high-risk obesity, announces that new data for its lead asset MTRX31 will be presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD), at the Allianz MiCo – Milan Convention Centre in Milan, Italy, from 28 September to 2 October 2026.MitoRx Therapeutics Appoints Clinical & Scientific Advisory Board to Guide the Development of MTRX31
Harwell Oxford, UK – 15 September 2026: MitoRx Therapeutics (“MitoRx”), a biotech company targeting the restoration of healthy mitochondrial metabolism in high-risk obesity, today announces the appointment of a Clinical & Scientific Advisory Board (CSAB) to guide the Company’s clinical development strategy for its lead asset, MTRX31.MitoRx Therapeutics Strengthens Leadership Team with C-Suite and Board Appointments to Support Next Phase of Growth
Harwell Oxford, UK – 9 June 2026: MitoRx Therapeutics (“MitoRx”), a biotech company targeting the restoration of healthy mitochondrial metabolism in high-risk obesity, announces the appointment of Alison Strutt, PhD, as Chief Financial Officer, and László Tankó, MD, PhD, DMSc, eMBA as Consultant Chief Medical Officer, effective immediately. The Company also announces the appointment of Sam Fazeli, PhD, as a Non-Executive Director.MitoRx Therapeutics presents promising preclinical data on MTRX31, a mitochondrial-targeted small molecule for metabolically unhealthy obesity, at the American Diabetes Association’s 2026 Scientific Sessions
Harwell Oxford, UK – 8 June 2026: MitoRx Therapeutics (“MitoRx”), a biotech company targeting the restoration of healthy mitochondrial metabolism in high-risk obesity, announces preclinical data for its lead asset, MTRX31, was presented at the American Diabetes Association’s 2026 Scientific Sessions (ADA 2026), taking place in New Orleans, Louisiana from 5-8 June.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding MitoRx Therapeutics
Sign Up For FreeTo access detailed company insights
MitoRx Therapeutics specializes in developing first-in-class small molecule therapeutics that modulate mitochondrial metabolism, primarily targeting obesity and other cardiometabolic diseases. Their innovative approach aims to facilitate weight loss while preserving lean mass, utilizing mitochondrial-targeted compounds that have shown efficacy in v... Read More
